Bavarian Nordic has acquired Emergent BioSolutions‘ travel health business for up to $380 million.
Upon closing of the transaction, Bavarian Nordic will pay Emergent $270 million in upfront cash consideration. Bavarian Nordic will also pay Emergent up to $30 million in sales-based milestones associated with commercial products and up to $80 million in development-based milestones associated with the CHIKV VLP program.
Bavarian Nordic will acquire Emergent’s manufacturing site in Bern, Switzerland, and development facilities in San Diego, California. Approximately 280 Emergent employees are expected to join Bavarian Nordic as part of the transaction that is expected to close in the second quarter of 2023, subject to regulatory clearance and customary closing conditions.
Bavarian Nordic specializes in the research, development and manufacture of cancer immunotherapies and vaccines for infectious diseases.
Emergent BioSolutions provides solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers.
According to data captured in the LevinPro HC database, this acquisition marks the 23rd Biotechnology deal of 2023. There were 141 Biotechnology transactions reported in 2022.
